David Gaylor, Ph.D., M.S. is a nationally recognized leader in the fields of biometry, statistics, and risk assessment who became affiliated with Sciences after retiring from the National Center for Toxicological Research (NCTR), where he served as the principal advisor to and spokesperson for the NCTR Director/FDA Associate Commissioner for Science on matters related to the planning, development, implementation and administration of health risk assessment policies reaching across a wide range of FDA's activities. Dr. Gaylor also serves as an Adjunct Professor of Statistics at the University of Arkansas for Medical Sciences. Dr. Gaylor has served on more than 50 national and international work groups and committees on many aspects of biometry, toxicology, and risk assessment. He is currently a member of the editorial board of four professional journals: Risk Analysis, Human Ecological Risk Assessment, Regulatory Toxicology and Pharmacology, and Toxicology and Industrial Health. Dr. Gaylor has also authored more than 170 journal articles, 25 book chapters, and 100 presentations on a wide range of issues.

Key Project Areas for Dr. Gaylor include:

  • Estimation of benchmark doses to refine the evaluation of the dose-response of toxic substances, and the development of procedures for benchmark dose estimation.
  • Development of protocols to evaluate carcinogenesis, teratogenesis, and mutagenesis.
  • Development of novel and advanced techniques for quantitative risk assessment.

Recent Publications and Presentations:

Gaylor, DW. (2005) Are tumor incidence rates telling us what we need to know about carcinogens? Regulatory Toxicol Pharmacol, 41:128-133. (abstract)

Gaylor, DW and Slikker, W. (2004) Role of the standard deviation in the estimation of benchmark doses with continuous data. Risk Analysis, 24:1683-1687. (abstract)

Gaylor, DW and Aylward, LL. (2004) An evaluation of benchmark dose methodology for non-cancer continuous-data health effects in animals due to exposures to dioxin (TCDD). Regulatory Toxicol Pharmacol, 40:9-17. (abstract)

Gaylor, DW. (2005) Risk/Benefit assessments of human diseases: optimum dose for intervention. Risk Analysis, 25:161-168. (abstract)

Krewski, D, Bakshi, K, Garrett, R., Falke, E., Rusch, G. and Gaylor, DW. (2004) Development of acute exposure guideline levels for airborne exposures to hazardous substances. Regulatory Toxicol Pharmacol, 39:184-201. (abstract)

View Resumé (PDF format)